According to Zacks, “Icosavax Inc. is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company’s virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc. is based in SEATTLE. “
NASDAQ:ICVX opened at $10.23 on Tuesday. Icosavax has a 1 year low of $4.00 and a 1 year high of $49.99. The firm’s fifty day simple moving average is $8.42 and its 200 day simple moving average is $15.80. The firm has a market capitalization of $406.44 million and a PE ratio of -1.96.
In other news, insider Cassia Cearley sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 7th. The shares were sold at an average price of $17.16, for a total transaction of $171,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark Mcdade acquired 42,225 shares of Icosavax stock in a transaction dated Friday, April 1st. The shares were acquired at an average cost of $7.10 per share, with a total value of $299,797.50. Following the completion of the acquisition, the director now directly owns 50,243 shares in the company, valued at approximately $356,725.30. The disclosure for this purchase can be found here.
Several large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Icosavax by 3.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,732 shares of the company’s stock worth $772,000 after acquiring an additional 975 shares during the period. Royal Bank of Canada bought a new position in Icosavax during the 3rd quarter valued at about $44,000. Citigroup Inc. bought a new position in Icosavax during the 3rd quarter valued at about $45,000. Swiss National Bank lifted its holdings in Icosavax by 6.1% during the 1st quarter. Swiss National Bank now owns 27,700 shares of the company’s stock valued at $195,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Icosavax by 161.2% during the 4th quarter. Bank of America Corp DE now owns 3,594 shares of the company’s stock valued at $82,000 after purchasing an additional 2,218 shares during the last quarter. 79.43% of the stock is owned by institutional investors.
About Icosavax (Get Rating)
Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial.
- Get a free copy of the StockNews.com research report on Icosavax (ICVX)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.